LIGAND PHARMACEUTICALS INCORPORATED (LGND) Deferred State and Local Income Tax Expense (Benefit)

LIGAND PHARMACEUTICALS INCORPORATED Deferred State and Local Income Tax Expense (Benefit)

LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Deferred State and Local Income Tax Expense (Benefit) of $574.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Expense Statement › Income Tax

us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-27

• LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2025 was $574.00K, a 645.45% increase from fiscal 2024.
• LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2024 was $77.00K, a 88.24% decline from fiscal 2023.
• LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2023 was $655.00K, a 98.08% decline from fiscal 2022.
• LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2022 was $34.14M.